Determination of pergolide in horse plasma by UPLC-MS/MS for pharmacokinetic applications

Journal of Pharmaceutical and Biomedical Analysis

Volumn 94, Issue , 2014, Pages 54-57

  Jacobson, Glenn A ^a   Pirie, Adam ^a   Edwards, Scott ^b   Hughes, Kristopher J ^b   Rendle, David I ^b   Davies, Noel W ^c  

^a UNIVERSITY OF TASMANIA   (Australia)

^b CHARLES STURT UNIVERSITY   (Australia)

^c UNIVERSITY OF TASMANIA   (Australia)

Author keywords

Equine Cushing's disease; Pharmacokinetics; Pituitary pars intermedia dysfunction; PPID; UPLC MS MS

Indexed keywords

EQUINE CUSHING'S DISEASE; PHARMACOKINETICS; PITUITARY PARS INTERMEDIA DYSFUNCTION; PPID; UPLC-MS/MS;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HORSES; LIMIT OF DETECTION; PERGOLIDE; TANDEM MASS SPECTROMETRY;

EID: 84894115075     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2014.01.016     Document Type: Article

References (9)

1. McFarlane D. Equine pituitary pars intermedia dysfunction. Vet. Clin. North Am. Equine Pract. 2011, 27:93-113.
2. Beech J. Treatment of hypophysial adenomas. Compend. Contin. Educ. Pract. Vet. 1994, 921-923.
3. Perkins G.A., Lamb S., Erb H.N., Schanbacher B., Nydam D.V., Divers T.J. Plasma adrenocorticotropin (ACTH) concentrations and clinical response in horses treated for equine Cushing's disease with cyproheptadine or pergolide. Equine Vet. J. 2002, 34:679-685.
4. Donaldson M.T., LaMonte B.H., Morresey P., Smith G., Beech J. Treatment with pergolide or cyproheptadine of pituitary pars intermedia dysfunction (equine Cushing's disease). J. Vet. Intern. Med. 2002, 16:742-746.
5. Rohrbach B.W., Stafford J.R., Clermont R.S., Reed S.M., Schott H.C., Andrews F.M. Diagnostic frequency, response to therapy, and long-term prognosis among horses and ponies with pituitary par intermedia dysfunction, 1993-2004. J. Vet. Intern. Med. 2012, 26:1027-1034.
6. Thalamas C., Rajman I., Kulisevsky J., Lledo A., Mackie A.E., Blin O., Gillespie T.A., Seger M., Rascol O. Pergolide: multiple-dose pharmacokinetics in patients with mild to moderate Parkinson disease. Clin. Neuropharmacol. 2005, 28:120-125.
7. Gehring R., Beard L., Wright A., Coetzee J., Havel J., Apley M. Single-dose oral pharmacokinetics of pergolide mesylate in healthy adult mares. Vet. Ther. 2010, 11:E1-E8.
8. Hughes N., Winnik W., Dunyach J.J., Amad M., Splendore M., Paul G. High-sensitivity quantitation of cabergoline and pergolide using a triple-quadrupole mass spectrometer with enhanced mass-resolution capabilities. J. Mass Spectrom. 2003, 38:743-751.
9. Whitmire M., Ammerman J., de Lisio P., Killmer J., Kyle D., Mainstone E., Porter L., Zhang T. LC-MS/MS bioanalysis method development, validation, and sample analysis: points to consider when conducting nonclinical and clinical studies in accordance with current regulatory guidances. Anal. Bioanal. Tech. 2011, S4:1-10.